{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 470614898
| IUPAC_name = (4α,5α,17β)-3,17-dihydroxy-4,5-epoxyandrost-2-ene-2-carbonitrile
| image = Trilostane.svg

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|monograph|tigan}}
| pregnancy_AU = <!-- A, B1, B2, B3, C, D, X -->
| pregnancy_US = <!-- A, B, C, D, X -->
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
| legal_US_comment = Veterinary use
| routes_of_administration = oral

<!--Pharmacokinetic data-->
| metabolism = Hepatic
| elimination_half-life = 8 hours

<!--Identifiers-->
| IUPHAR_ligand = 6850
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 13647-35-3
| ATC_prefix = H02
| ATC_suffix = CA01
| PubChem = 656583
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
 | DrugBank = DB01108
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 570949
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = L0FPV48Q5R
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01180
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 32260
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1200907

<!--Chemical data-->
| C=20 | H=27 | N=1 | O=3 
| molecular_weight = 329.433 g/mol
| smiles = N#C\C4=C(/O)[C@H]5O[C@]35[C@]([C@@H]2[C@H]([C@H]1[C@]([C@@H](O)CC1)(C)CC2)CC3)(C)C4
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C20H27NO3/c1-18-7-6-14-12(13(18)3-4-15(18)22)5-8-20-17(24-20)16(23)11(10-21)9-19(14,20)2/h12-15,17,22-23H,3-9H2,1-2H3/t12-,13-,14-,15-,17+,18-,19+,20+/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = KVJXBPDAXMEYOA-CXANFOAXSA-N
| synonyms = 4α,5-Epoxy-3,17β-dihydroxy-5α-androst-2-ene-2-carbonitrile
}}

'''Trilostane''' is a [[steroidogenesis inhibitor]] which is used in the treatment of [[Cushing's syndrome]].<ref name="pmid233687">{{cite journal |vauthors=Komanicky P, Spark RF, Melby JC |title=Treatment of Cushing's syndrome with trilostane (WIN 24,540), an inhibitor of adrenal steroid biosynthesis |journal=J. Clin. Endocrinol. Metab. |volume=47 |issue=5 |pages=1042–51 |year=1978 |pmid=233687 |doi=10.1210/jcem-47-5-1042 |url=}}</ref><ref>{{cite web|url=http://www.wedgewoodpetrx.com/learning-center/professional-monographs/trilostane-for-veterinary-use.html|title=Trilostane for Veterinary Use|author=Forney, Barbara|publisher=Wedgewood Pharmacy|accessdate=5 April 2011}}</ref>

It was withdrawn from human use in the United States market in April 1994.<ref name=Cook/><ref>{{cite web|url=http://www.drugs.com/cons/trilostane.html|title=Trilostane consumer information|date=4 January 2009|publisher=Drugs.com|accessdate=3 April 2011|archiveurl=https://web.archive.org/web/20080212180719/http://www.drugs.com/cons/trilostane.html|archivedate=12 February 2008}}</ref> The drug was previously available in the United Kingdom for use in humans under the brand name '''Modrenal''' for the treatment of Cushing's disease and for breast cancer.<ref name=DrugsUK>{{cite web|url=http://www.drugs.com/uk/modrenal-943.html|title=Modrenal consumer information|publisher=Drugs.com UK|accessdate=3 April 2011}}</ref><ref>{{cite web|url=http://www.medicines.org.uk/EMC/medicine/17410/SPC/Modrenal/|title=Modrenal|publisher=electronic Medicines Compendium UK|accessdate=3 April 2011}}</ref><ref name=Church>{{cite web|url=http://caninediabeteswiki.wikkii.com/wiki/File:Australian_veterinary_journal_october_2003.pdf|title=Trilostane treatment in dogs with pituitary-dependent hyperadrenocorticism |vauthors =Braddock, JA, Church, DB, Robertson, ID, Watson, ADJ|date=October 2003|publisher=Australian Veterinary Journal|pages=18 of 63|accessdate=5 April 2011}} ([[PDF]])</ref>  It was approved in the United States in 2008 for the treatment of Cushing's disease (hyperadrenocorticism) in dogs under the brand name '''Vetoryl'''.<ref name=Approval/> It was available by prescription in the UK under the '''Vetoryl''' brand name for some time before it was approved in the US.<ref name=NOAH/> The drug is also used to treat the skin disorder Alopecia X in dogs.<ref name=Cook>{{cite web|url=http://veterinarymedicine.dvm360.com/vetmed/article/articleDetail.jsp?id=491107&sk=&date=&pageID=5|title=Trilostane: A therapeutic consideration for canine hyperadrenocorticism|author=Cook, Audrey K.|date=1 February 2008|publisher=DVM 360|accessdate=5 April 2011}}</ref><ref>{{cite web|url=http://caninediabeteswiki.wikkii.com/w/images/caninediabeteswiki/uploads/8/87/2006symposiumproceedings.pdf|title=Alopecia: Is an Endocrine Disorder Responsible?|author=Hillier, Andrew|year=2006|page=12 of 67|publisher=Ohio State University Endocrinology Symposium|accessdate=8 April 2011}} ([[PDF]])</ref><ref>{{cite web|url=http://www.solidgoldsamoyeds.com/Treatment%20with%20trilostane.pdf|title=Treatment of Canine Alopecia X with trilostane|author1=Cerundolo, Rosario|author2= Lloyd, David H.|author3=Persechino, Angelo|author4=Evans, Helen|author5=Cauvin, Andria|year=2004|publisher=European Society of Veterinary Dermatology|accessdate=16 May 2011}} ([[PDF]])</ref>
It is also the first drug approved to treat both pituitary- and adrenal-dependent Cushing's in dogs. This prescription drug works by stopping the production of cortisol in the adrenal glands.<ref>{{cite web|url=http://caninediabeteswiki.wikkii.com/w/images/caninediabeteswiki/uploads/8/87/2006symposiumproceedings.pdf|title=Trilostane-5 Years of Clinical Experience for the Treatment of Cushing's Disease|author=Reusch, Claudia E.|year=2006|publisher=Ohio State University Endocrinology Symposium|pages=17–19|accessdate=5 April 2011}} ([[PDF]])</ref><ref>{{cite web|url=http://www.vin.com/proceedings/Proceedings.plx?CID=WSAVA2010&Category=&PID=56127&O=Generic|title=Trilostane-A Review of a Success Story|author=Reusch, Claudia E.|year=2010|publisher=World Small Animal Veterinary Association (WSAVA)|accessdate=5 April 2011}}</ref> In studies of the drug, the most common side effects were vomiting, lack of energy, diarrhea, and weight loss. Trilostane should not be given to a dog that:
#has kidney or liver disease;<ref name=NOAH>{{Cite web|url=http://www.noahcompendium.co.uk/Dechra_Veterinary_Products_Ltd/Vetoryl_ACY-reg_ADs-_10_mg_Hard_Capsules_for_Dogs/-36949.html|title=Vetoryl-Contraindications|publisher=NOAH Compendium of Animal Health-National Office of Animal Health UK|accessdate=3 April 2011}}</ref><ref name=Dechra>{{cite web|url=http://www.dechra-us.com/files/dechra/Downloads/Pharma/Datasheets/Vetoryl_10_mg_Hard_Capsules_for_Dogs_16-12-10.pdf|title=Dechra US Datasheet-Vetoryl|publisher=Dechra US|accessdate=3 April 2011}} ([[PDF]])</ref>
#takes certain medications used to treat heart disease; {{citation needed|date=April 2011}}
#is pregnant, nursing or intended for breeding <ref name=NOAH/><ref name=Dechra/>
The safety and effectiveness of trilostane were shown in several studies. Success was measured by improvements in both blood test results and physical symptoms (increased appetite and activity level, and decreased panting, thirst and urination).<ref name=Church/><ref name=FDA/>

Only one other drug, Anipryl (veterinary brand name) [[selegiline]], is FDA-approved to treat Cushing's disease in dogs, but only to treat uncomplicated, pituitary-dependent Cushing's.<ref>{{cite web|url=http://www.drugs.com/vet/anipryl-tablets.html|title=Anipryl consumer information|publisher=Drugs.com Vet|accessdate=3 April 2011}}</ref> The only previous treatment for the disease was the use of [[Mitotane]] (brand name Lysodren) off-label.<ref name=FDA>{{cite web|url=http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm151209.htm|title=Treating Cushing's Disease in Dogs|publisher=US Food and Drug Administration|accessdate=3 April 2011}}</ref><ref>{{cite journal|title=Medical management of pituitary-dependent hyperadrenocorticism: mitotane versus trilostane|author=Reine, NJ.|journal=Clinical Tech-Small Animal Practice|year=2007|pmid=17542193|doi=10.1053/j.ctsap.2007.02.003|volume=22|issue=1|pages=18-25}}</ref>

It has been used as a [[progesterone]] inhibitor.<ref name="pmid12042266">{{cite journal |vauthors =le Roux PA, Tregoning SK, Zinn PM, van der Spuy ZM |title=Inhibition of progesterone secretion with trilostane for mid-trimester termination of pregnancy: randomized controlled trials |journal=Human reproduction (Oxford, England) |volume=17 |issue=6 |pages=1483–9 |date=June 2002 |pmid=12042266 |doi= 10.1093/humrep/17.6.1483|url=http://humrep.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=12042266}}</ref>

A number of compounding pharmacies in the US sell the product.  Since the US approval of Vetoryl in December 2008,<ref name=Approval>{{cite web|url=http://www.fda.gov/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/ucm049823.htm|title=Vetoryl approval information|date=5 December 2008|publisher=Food and Drug Administration|accessdate=3 April 2011}}</ref> compounding pharmacies are no longer able to use a bulk drug product for compounding purposes, but must prepare the compounded drug from Vetoryl.<ref>{{cite web|url=http://www.fda.gov/AnimalVeterinary/SafetyHealth/ProductSafetyInformation/ucm182039.htm|title=VETORYL (trilostane) Capsules Letter - Pharmacy Professionals|date=11 September 2009|publisher=Food and Drug Administration|accessdate=3 April 2011}}</ref>

It is an [[enzyme inhibitor|inhibitor]] of [[3β-hydroxysteroid dehydrogenase]] (3β-HSD), as well as of other [[enzyme]]s involved in [[steroidogenesis]].<ref name="pmid21295836">{{cite journal |author1=de Gier J |author2=Wolthers CH |author3=Galac S |author4=Okkens AC |author5=Kooistra HS |title=Effects of the 3β-hydroxysteroid dehydrogenase inhibitor trilostane on luteal progesterone production in the dog |journal=Theriogenology |volume=75 |issue=7 |pages=1271–9 |date=April 2011 |pmid=21295836 |doi=10.1016/j.theriogenology.2010.11.041 |url=http://linkinghub.elsevier.com/retrieve/pii/S0093-691X(10)00634-5}}</ref>

==Chemistry==
The compound is prepared from testosterone in a four-step synthesis.

==References==
{{Reflist}}

==External links==
*[http://caninediabeteswiki.wikkii.com/w/images/caninediabeteswiki/uploads/a/ab/SPC_183023.pdf Trilostane (Vetoryl) information from Veterinary Medicines Directorate, UK].  Includes precautionary use regarding concurrent medical conditions, possible side effects, and possible interaction with other drugs. ([[PDF]])

{{Antiglucocorticoids}}
{{Glucocorticoidics}}

[[Category:3β-Hydroxysteroid dehydrogenase inhibitors]]
[[Category:11β-Hydroxylase inhibitors]]
[[Category:Androstanes]]
[[Category:Cholesterol side-chain cleavage enzyme inhibitors]]
[[Category:Hormonal agents]]
[[Category:Nitriles]]
[[Category:Oxidoreductase inhibitors]]
[[Category:Withdrawn drugs]]